responses in the body. They also play a significant role in
cancer cell growth, metastasis, invasiveness, cell survival and
induction of tumor necrosis factor (TNF) [7]. Many COX-2 or
5-LOX inhibitors have been developed as drugs to treat
inflammation [10]. In this study Taxusabietane A exhibited
significant inhibition of the lipoxygenase showing its strong
potential to be developed as anti-inflammatory drug. Molecular
docking studies revealed that its compact skeleton is the
basic reason of how it holds strong contacts with the
important amino acid side chains inside the active site as
well as adjoining sites of the enzyme thus preventing its proinflammatory
role.
Carrageenan-induced paw edema being an in-vivo investigational
model for acute inflammation which been extensively
used to determine the anti-inflammatory effect of new
investigational agents [7–9]. Taxusabietane A further established
its significant (pb0.05) anti-inflammatory potential in
in-vivo study by controlling biphasic inflammatory events
induced by carrageenan. The early phase (90–180 min) of the
inflammation is due to the release of histamine, serotonin and